Suzhou Saifu Launches Non-Clinical One-Stop Service Platform for Innovative Drug Development
On the morning of May 18, the grand opening ceremony of Suzhou Saifu’s One-Stop Non-Clinical Service Platform was held in Suzhou Industrial Park. Ni Qian, Member of the Working Committee and Deputy Director of the Administrative Committee of Suzhou Industrial Park; Chen Li, Deputy Secretary of the Party Working Committee and Director of the Administrative Committee of Dushu Lake Science and Education Innovation District; Pan Yu, Party Group Secretary and Director of the Science and Technology Innovation Commission of Suzhou Industrial Park; Xiao Shitao, Chairman of the Suzhou Industrial Park Association for Science and Technology, Deputy Director of the Science and Technology Innovation Commission, and Director of the Science and Technology Investment Promotion Center, together with numerous partners of Saifu Pharma, industry friends, and all employees of Suzhou Saifu, gathered to jointly witness this historically significant moment.PART.01 Check-in Ceremony
At 9:00 a.m., guests arrived successively at the ceremony venue, completed registration in an orderly manner, and extended their congratulations to Suzhou Saifu, creating a warm and harmonious atmosphere.
PART.02 Laboratory Tour
Suzhou CytoFusion staff guided guests on a batch-by-batch tour of its internationally standardized laboratory animal facilities.Facilities and FunctionsNeng Laboratory.
PART.03 Opening Ceremony
Leaders' Address
Address by Mr. Liu Yang, Founder and Chairman of Saifu Pharmaceutical
In his address, Mr. Liu Yang expressed his gratitude for the strong support from Suzhou Industrial Park, shareholders, and partners, as well as for the acceptance and recognition by customers. He reviewed the development history of Saifu Pharma, provided a brief overview of Suzhou Saifu, and outlined a vibrant vision for its future growth, allowing attendees to genuinely appreciate the entrepreneurial spirit of the Saifu team and gain insight into the promising prospects of Saifu Pharma.
Address by Chen Li, Deputy Secretary of the Party Working Committee and Director of the Administrative Committee of Suzhou Dushu Lake Science and Education Innovation District
Ms. Chen Li stated that Suzhou Saifu is a key innovative pharmaceutical technology service platform introduced to the industrial park. She expressed hope that, taking this opening as an opportunity, the company would continue to provide first-class scientific research and experimental services meeting international standards for innovative drug R&D enterprises in the park and even globally, thereby accelerating and empowering the development of the regional biopharmaceutical industry.
Address by Professor Yang Yong, Member of the Standing Committee of the Party Committee and Vice President of China Pharmaceutical University
Professor Yang Yong emphasized the promising vision of expanding future collaborations with Saifu Pharma in the field of scientific research.
Strategic Partnership Signing
Suzhou Saifu has signed eight strategic cooperation agreements with partners including the School of Pharmacy at East China Normal University, the College of Animal Science and Technology at Nanjing Agricultural University, Bionavigen Oncology LLC, Quanxin Biologics, Nanjing Chia Tai Tianqing Pharmaceutical, Shenxi Biologics, Yimufeng Biologics, Suzhou Institute for Drug Research of the Chinese Academy of Sciences, Porton Biopharma, Lidi Biotechnology, Kelin Likang, and Shanghai Pudong Development Bank. These agreements cover the joint establishment of an end-to-end one-stop innovative drug service platform, internship and practice bases for master’s and doctoral students in biological and pharmaceutical engineering, and an innovative drug R&D platform, aiming to jointly explore broader development opportunities in the biopharmaceutical sector.
East China Normal University School of Pharmacy and Suzhou Cyagen Sign Strategic Partnership Agreement
Nanjing Agricultural University’s College of Animal Science and Technology Signs Strategic Agreement with Suzhou SaiFu
Bionavigen Oncology LLC. Signs Strategic Agreement with Suzhou Cyagen
Quanxin Bio and Suzhou Saifu Sign Strategic Partnership Agreement
Nanjing Chia Tai Tianqing and Suzhou SaiFu Sign Strategic Partnership Agreement
Shenxi Biotech and Suzhou Saifu Sign Strategic Agreement
Yimufeng Bio and Suzhou Saifu Sign Strategic Agreement
Suzhou Institute of Chinese Academy of Sciences for Drug Research, Lidi Biotech, Porton Bio, Suzhou Saifu,
Colinlicon and Shanghai Pudong Development Bank Sign Strategic Partnership Agreement
Push Rod Ceremony
As the countdown concluded, several leaders and guests jointly pushed the lever symbolizing “higher and farther,” officially launching the Suzhou Cyagen One-Stop Preclinical Drug Development Service Platform. This marks the beginning of a new chapter for Cyagen Pharmaceuticals!
Suzhou Saifu New Drug Technical Services Co., Ltd. (hereinafter referred to as “Suzhou Saifu”) is an international contract research organization (CRO) specializing in non-clinical research technical services for new drugs. The company provides premier technical services that meet the new drug registration and filing requirements of global regulatory authorities, including the National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA). These services encompass pharmacology and efficacy studies, drug metabolism (PK/ADME) assessments, and toxicology testing conducted in compliance with Good Laboratory Practice (GLP) standards set by the Organisation for Economic Co-operation and Development (OECD), the FDA, and the NMPA. Suzhou Saifu remains committed to enhancing its technical service capabilities, accelerating the translation and application of new drugs from laboratory to clinical settings, empowering pharmaceutical R&D enterprises, and ultimately benefiting the general public.
Beijing Saifu Pharmaceutical Research Institute Co., Ltd. (hereinafter referred to as “Saifu Pharma”) was established in 2016, with the commitment to becoming a world-class one-stop pharmaceutical CRO service provider. It offers top-tier pharmaceutical CRO evaluation services, integrated with technology development, financing, and innovative drug product commercialization support. The company provides comprehensive R&D planning for innovative medicines, accelerating the drug development process and facilitating faster corporate growth. Its departments include pharmaceutical R&D consulting, NMPA/FDA regulatory submission, antibody drug discovery, early-stage drug screening and druggability assessment, pharmacology and efficacy evaluation, pharmacokinetic evaluation, non-clinical safety assessment, biological sample testing, and companion diagnostic product development, enabling it to deliver professional one-stop pharmaceutical R&D services to clients.
The Company has obtained various qualifications and certificates, including international AAALAC accreditation, ten NMPA GLP certifications, OECD GLP compliance, CMA certification from the Certification and Accreditation Administration of China (CNCA), A2LA ISO 15189 accreditation in the United States, CAP accreditation in the United States, and registration as a Biosafety Level 2 (BSL-2) laboratory. Its research reports are widely recognized in China, the United States, Europe, and other countries, supporting global regulatory submissions. The Company has successively been honored as a National “Little Giant” Enterprise in Specialized, Refined, Differential, and Innovative Fields, a National High-Tech Enterprise, an Enterprise Technology Center in Beijing and Hebei Province, a Beijing Enterprise Science and Technology Research and Development Institution, a Beijing Public Service Platform for Small and Medium-sized Enterprises, and a Hebei Provincial Technology Innovation Center. It also operates two postdoctoral research stations.